Skip to content

Study · Animal study (in vivo) · rat · 2007

7 results

Effect of recombinant human thymosin-alpha1, an immuno-modulating peptide with 28 amino acids, on the activity of cytochrome P450s.

Wang B, He F, Lin Y, Huang M, Zhou SF

Drug metabolism letters1 Aug 2007Cited by 5 (Europe PMC)

PMID19356044 (opens in a new tab)DOI10.2174/187231207781369825 (opens in a new tab)PepBankPUB-19356044
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In rats, rh-T alpha 1 at either dosage did not significantly alter liver weight.

    In plain wordsIn rats, thymosin-alpha1 did not significantly change liver weight.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeLiver weight
    Study

    ratn: not reported in source

    Rats given rh-T alpha 1 subcutaneously for two weeks
    Outcome group
    Adverse events · Pharmacology
    Studied dose
    150, 300 or 600 microg/kg daily · subcutaneous · two weeksAs given in this study (rat).

    Source sentences

    Summary
    As to in vivo studies, treatment of rh-T alpha 1 at either dosage did not significantly alter the liver weight.
    2 context sentences
    Summary · context
    In this study, we examined the effects of recombinant human thymosin-alpha1 (rh-T alpha 1) on hepatic cytochrome P450 (CYP) enzyme activity in rats in vitro and in vivo.
    Summary · context
    For the in vitro experiments, rh-T alpha 1 was incubated with the probe drugs and the liver microsomes from rats, while rh-T alpha 1 was administered to rats subcutaneously at 150, 300, or 600 microg/kg daily for two weeks in in vivo studies.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats pretreated with rh-T alpha 1 at 150, 300 or 600 microg/kg for two weeks, hepatic CYP2E1 activity was significantly increased.

    In plain wordsIn rats, two weeks of thymosin-alpha1 raised the activity of the liver enzyme CYP2E1.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCYP2E1 activity after pretreatment
    Study

    ratn: not reported in source

    Rats given rh-T alpha 1 subcutaneously for two weeks
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    150, 300 or 600 microg/kg daily · subcutaneous · two weeksAs given in this study (rat).

    Source sentences

    Summary
    an ex vivo study demonstrated that the activity of rat hepatic CYP2E1 was significantly increased by pretreatment of rh-T alpha 1 at the three doses for two weeks
    2 context sentences
    Summary · context
    In this study, we examined the effects of recombinant human thymosin-alpha1 (rh-T alpha 1) on hepatic cytochrome P450 (CYP) enzyme activity in rats in vitro and in vivo.
    Summary · context
    For the in vitro experiments, rh-T alpha 1 was incubated with the probe drugs and the liver microsomes from rats, while rh-T alpha 1 was administered to rats subcutaneously at 150, 300, or 600 microg/kg daily for two weeks in in vivo studies.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats pretreated with rh-T alpha 1 at 600 microg/kg, hepatic CYP1A2 activity was significantly increased.

    In plain wordsIn rats given the highest dose of thymosin-alpha1, the activity of the liver enzyme CYP1A2 rose.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCYP1A2 activity after pretreatment
    Study

    ratn: not reported in source

    Rats given rh-T alpha 1 subcutaneously for two weeks
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    600 microg/kg daily · subcutaneous · two weeksAs given in this study (rat).

    Source sentences

    Summary
    the activities of CYP1A2, CYP2D2, and CYP3A1/2 were also significantly increased in rats pretreated with rh-T alpha 1 at 600 microg/kg.
    2 context sentences
    Summary · context
    In this study, we examined the effects of recombinant human thymosin-alpha1 (rh-T alpha 1) on hepatic cytochrome P450 (CYP) enzyme activity in rats in vitro and in vivo.
    Summary · context
    For the in vitro experiments, rh-T alpha 1 was incubated with the probe drugs and the liver microsomes from rats, while rh-T alpha 1 was administered to rats subcutaneously at 150, 300, or 600 microg/kg daily for two weeks in in vivo studies.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats pretreated with rh-T alpha 1 at 600 microg/kg, hepatic CYP2D2 activity was significantly increased.

    In plain wordsIn rats given the highest dose of thymosin-alpha1, the activity of the liver enzyme CYP2D2 rose.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCYP2D2 activity after pretreatment
    Study

    ratn: not reported in source

    Rats given rh-T alpha 1 subcutaneously for two weeks
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    600 microg/kg daily · subcutaneous · two weeksAs given in this study (rat).

    Source sentences

    Summary
    the activities of CYP1A2, CYP2D2, and CYP3A1/2 were also significantly increased in rats pretreated with rh-T alpha 1 at 600 microg/kg.
    2 context sentences
    Summary · context
    In this study, we examined the effects of recombinant human thymosin-alpha1 (rh-T alpha 1) on hepatic cytochrome P450 (CYP) enzyme activity in rats in vitro and in vivo.
    Summary · context
    For the in vitro experiments, rh-T alpha 1 was incubated with the probe drugs and the liver microsomes from rats, while rh-T alpha 1 was administered to rats subcutaneously at 150, 300, or 600 microg/kg daily for two weeks in in vivo studies.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats pretreated with rh-T alpha 1 at 600 microg/kg, hepatic CYP3A1/2 activity was significantly increased.

    In plain wordsIn rats given the highest dose of thymosin-alpha1, the activity of the liver enzyme CYP3A1/2 rose.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCYP3A1/2 activity after pretreatment
    Study

    ratn: not reported in source

    Rats given rh-T alpha 1 subcutaneously for two weeks
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    600 microg/kg daily · subcutaneous · two weeksAs given in this study (rat).

    Source sentences

    Summary
    the activities of CYP1A2, CYP2D2, and CYP3A1/2 were also significantly increased in rats pretreated with rh-T alpha 1 at 600 microg/kg.
    2 context sentences
    Summary · context
    In this study, we examined the effects of recombinant human thymosin-alpha1 (rh-T alpha 1) on hepatic cytochrome P450 (CYP) enzyme activity in rats in vitro and in vivo.
    Summary · context
    For the in vitro experiments, rh-T alpha 1 was incubated with the probe drugs and the liver microsomes from rats, while rh-T alpha 1 was administered to rats subcutaneously at 150, 300, or 600 microg/kg daily for two weeks in in vivo studies.
  6. 06LabIn vitro (cell-free)Mechanism

    In rat liver microsomes, rh-T alpha 1 at 20 and 50 micromol/l significantly inhibited CYP2E1 activity.

    In plain wordsIn lab tests with rat liver preparations, thymosin-alpha1 reduced the activity of the CYP2E1 enzyme.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseCYP2E1 activity in vitro
    Study

    ratn: not reported in source

    Rat liver microsomes
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 and 50 micromol/lAs given in this study (rat).

    Measurements

    Concentration with CYP2E1 inhibition
    20 to 50 micromol/l
    rat liver microsomes

    Source sentences

    Summary
    Co-incubation of rh-T alpha(1) at the concentration of 20 and 50 micromol/l with the liver microsomes significantly inhibited CYP2E1 activity, whereas there was no significant effect on the activities of CYP1A2, CYP2C6, CYP2C11, CYP2D2, and CYP3A1/2.
    2 context sentences
    Summary · context
    In this study, we examined the effects of recombinant human thymosin-alpha1 (rh-T alpha 1) on hepatic cytochrome P450 (CYP) enzyme activity in rats in vitro and in vivo.
    Summary · context
    For the in vitro experiments, rh-T alpha 1 was incubated with the probe drugs and the liver microsomes from rats, while rh-T alpha 1 was administered to rats subcutaneously at 150, 300, or 600 microg/kg daily for two weeks in in vivo studies.
  7. 07LabIn vitro (cell-free)Mechanism

    In rat liver microsomes, rh-T alpha 1 had no significant effect on the activities of CYP1A2, CYP2C6, CYP2C11, CYP2D2 and CYP3A1/2.

    In plain wordsIn lab tests with rat liver preparations, thymosin-alpha1 did not change five other liver enzymes tested.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCYP1A2, CYP2C6, CYP2C11, CYP2D2 and CYP3A1/2 activity in vitro
    Study

    ratn: not reported in source

    Rat liver microsomes
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 and 50 micromol/lAs given in this study (rat).

    Source sentences

    Summary
    whereas there was no significant effect on the activities of CYP1A2, CYP2C6, CYP2C11, CYP2D2, and CYP3A1/2.
    2 context sentences
    Summary · context
    In this study, we examined the effects of recombinant human thymosin-alpha1 (rh-T alpha 1) on hepatic cytochrome P450 (CYP) enzyme activity in rats in vitro and in vivo.
    Summary · context
    For the in vitro experiments, rh-T alpha 1 was incubated with the probe drugs and the liver microsomes from rats, while rh-T alpha 1 was administered to rats subcutaneously at 150, 300, or 600 microg/kg daily for two weeks in in vivo studies.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.